ceralasertib

News

AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.

News

Scribe Therapeutics has become the latest biotech to announce plans to list on the Nasdaq as it advances its spin on CRISPR-based therapeutics.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.